IRLAB Therapeutics AB (publ) (FRA:6IRA)

Market Cap	11.76M -51.3%
Revenue (ttm)	5.31M -39.3%
Net Income	-10.17M
EPS	-0.15
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.1368
Previous Close	0.1398
Day's Range	0.1368 - 0.1368
52-Week Range	0.1330 - 0.1868
Beta	n/a
RSI	40.83
Earnings Date	May 6, 2026

About IRLAB Therapeutics AB

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson’s disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson’s disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of falling and falls in Parkinson’s disease, and in a Phase IIA clinical tri...

• Industry: Pharmaceutical Preparations
• Founded: 2013
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6IRA

Financial Performance

In 2025, IRLAB Therapeutics AB's revenue was 57.46 million, a decrease of -39.28% compared to the previous year's 94.63 million. Losses were -110.01 million, 32.3% more than in 2024.

Financial numbers in SEK